Interfering with nucleotide excision by the coronavirus 3′-to-5′ exoribonuclease

• Published in: Nucleic acids research Vol. 51; no. 1; pp. 315 - 336
• Main Authors: Chinthapatla, Rukesh, Sotoudegan, Mohamad, Srivastava, Pankaj, Anderson, Thomas K, Moustafa, Ibrahim M, Passow, Kellan T, Kennelly, Samantha A, Moorthy, Ramkumar, Dulin, David, Feng, Joy Y, Harki, Daniel A, Kirchdoerfer, Robert N, Cameron, Craig E, Arnold, Jamie J
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 11.01.2023
• Subjects: Antiviral Agents - pharmacology; COVID-19 Drug Treatment; Drug Design; Exoribonucleases - metabolism; Humans; Nucleic Acid Enzymes; Ribonucleotides - chemistry; RNA, Viral - genetics; RNA, Viral - metabolism; SARS-CoV-2 - genetics; SARS-CoV-2 - metabolism; Viral Nonstructural Proteins - metabolism; Virus Replication - genetics

Some of the most efficacious antiviral therapeutics are ribonucleos(t)ide analogs. The presence of a 3′-to-5′ proofreading exoribonuclease (ExoN) in coronaviruses diminishes the potency of many ribonucleotide analogs. The ability to interfere with ExoN activity will create new possibilities for cont...